CoChat

A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizures

Open access
Klein, Pavel, Schiemann, Jimmy, Sperling, Michael R., Whitesides, John, Liang, Wei, Stalvey, Tracy, Brandt, Christian, Kwan, Patrick · 2015 · Epilepsia
Cited by 239

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Summary: Objective: Brivaracetam (BRV), a selective and high‐affinity synaptic vesicle protein 2A ligand, is in development as adjunctive treatment for partial‐onset (focal) seizures (POS). This phase 3 study (N01358; NCT 01261325) aimed to confirm the efficacy and safety/tolerability of BRV in adults (≥16–80 years) with POS. Methods: This randomized, double‐blind, placebo‐controlled, multicenter study enrolled patients with uncontrolled POS despite ongoing treatment with 1–2 antiepileptic drugs. Patients exposed to levetiracetam ≤90 days before visit 1 were excluded. Patients entered an 8‐week prospective baseline period, followed by a 12‐week treatment period when they were randomized 1:1:1 to placebo (PBO), BRV 100 mg/day, or BRV 200 mg/day, started without up‐titration. The co‐primary efficacy outcomes were percent reduction over placebo in 28‐day adjusted POS frequency, and ≥50% responder rate based on percent reduction in POS frequency from baseline to the treatment period. Results: Seven hundred sixty‐eight patients were randomized; 760 were included in the efficacy analysis: 259, 252, and 249 in PBO, BRV 100 mg/day, and BRV 200 mg/day groups, respectively. Percent reduction over PBO in 28‐day adjusted seizure frequency (95% confidence interval [CI]) was 22.8% for BRV 100 mg/day (13.3–31.2%; p < 0.001) and 23.2% for BRV 200 mg/day (13.8–31.6%; p < 0.001). The ≥50% responder rate (odds ratio vs. PBO; 95% CI) was 21.6% for PBO, 38.9% for BRV 100 mg/day (2.39; 1.6–3.6; p < 0.001), and 37.8% for BRV 200 mg/day (2.19; 1.5–3.3; p < 0.001). Treatment‐emergent adverse events (TEAE s) occurred in 155 (59.4%) of 261 PBO patients versus 340 (67.6%) of 503 BRV‐treated patients (safety population). Discontinuation rates due to TEAE s were 3.8%, 8.3%, and 6.8% for PBO, BRV 100 mg/day, and BRV 200 mg/day, respectively. Most frequent TEAE s (PBO versus BRV) were somnolence (7.7% vs. 18.1%), dizziness (5.0% vs. 12.3%), and fatigue (3.8% vs. 9.5%). Significance: Adjunctive BRV 100 and 200 mg/day was efficacious in reducing POS in adults without concomitant levetiracetam use and was well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.13212

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 239

Metadata

Authors
Klein, P., Schiemann, J., Sperling, M. R., Whitesides, J., Liang, W., Stalvey, T., Brandt, C., & Kwan, P.
Venue
Epilepsia
Publisher
Wiley
Published
2015-10-16
Volume
56
Issue
12
Pages
1890-1898
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W1916788136
Cited by
239
References
5
FWCI
20.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.